~~<i id='29AC27A6D6'><strike id='29AC27A6D6'><tt id='29AC27A6D6'><pre id='29AC27A6D6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：comprehensive 2025-09-28 23:49:14 - browse：345

The FDA building -- First Opinion coverage from STAT — Adobe

WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： A disappointing year of Humira biosimilars

explore

focus

entertainment

focus

leisure time

RedCrossvolunteersdelivermealsattheRollingForkMotel,wheredisplacedfamiliesarelivingaftertheirhomeswe

WSS

Vaccine advisory panel ACIP left half staffed by HHS

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Biden report: The neurospychology of memory and aging

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

As the dark side of IVF slowly comes into focus, even more transparency is needed

The dental labor crisis is a moment of opportunity

hotspot

Wikipedia

explore

BioMarin wins approval for gene therapy to treat hemophilia A

BioAge raises $170M for combination therapy with Zepbound

ChatGPT in medicine: STAT answers readers' burning questions

Public health communication lessons from Covid

The high cost of giving birth even with insurance

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Hollywood unions extend contract negotiations for actors

To avoid data mishandling cases, universities eye AI and other tools

United colonoscopy coverage change 'may cost lives,' doctors say

Vaccine advisory panel ACIP left half staffed by HHS

explore

Behind warning on Apellis’s eye drug lies a conflict of interest

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Timeline: Special counsel's probe into Trump's handling of classified documents

Robert F. Kennedy is pitching centrism on health, even on abortion

Key House Republican on health care plans exit from Congress

As the dark side of IVF slowly comes into focus, even more transparency is needed

focus

entertainment

focus

leisure time